Azienda Ospedaliera Regionale San Carlo

The medical center is at the forefront of colorectal cancer research, focusing on innovative adjuvant therapies and treatment regimens for advanced stages of the disease.

• Adjuvant therapy in stage IV colorectal cancer
• Intermittent vs. continuous panitumumab plus FOLFIRI
• Valproic acid in combination with bevacizumab and oxaliplatin

These studies aim to improve disease-free survival and explore novel combinations to enhance treatment efficacy and patient quality of life.

Our center is dedicated to advancing the understanding and treatment of Cystic Fibrosis, with a focus on long-term safety and efficacy of combination therapies.

• Elexacaftor/tezacaftor/ivacaftor safety and efficacy

Research in this area is crucial for developing therapies that improve the quality of life for patients with this chronic condition.

The center is pioneering research in gastric and gastroesophageal cancer, focusing on the effectiveness of targeted therapies in patients with minimal residual disease.

• Trastuzumab deruxtecan plus fluoropyrimidine

These studies aim to enhance treatment outcomes by targeting specific cancer markers and improving patient survival rates.

Our institution is leading research in cardiac surgery and the management of bleeding, focusing on innovative approaches to reduce transfusion needs and improve surgical outcomes.

• Fibrinogen concentrate in complex cardiac surgery
• Landiolol in mitral valve surgery

These studies are pivotal in enhancing patient safety and recovery in cardiac procedures.

The center is advancing the treatment of metastatic renal cell carcinoma through innovative combination therapies aimed at improving patient outcomes.

• Axitinib intensification plus nivolumab

Research in this area focuses on optimizing therapeutic strategies to enhance efficacy and patient survival.

Our research in Acute Lymphoblastic Leukemia is focused on developing chemo-free strategies that leverage targeted therapies to improve survival rates.

• Ponatinib and blinatumomab combination therapy

This approach aims to reduce toxicity and resistance, offering a promising alternative to traditional chemotherapy.

The center is committed to advancing the treatment of triple negative breast cancer through the use of immunotherapy to improve disease-free survival.

• Adjuvant avelumab therapy

These studies are crucial in developing effective post-surgical treatment options for high-risk patients.

Our institution is at the forefront of lymphoma research, focusing on innovative treatment strategies for various subtypes of the disease.

• Prephase treatment with prednisone and Vitamin D
• Shortened vs. standard chemotherapy in Follicular Lymphoma
• Ibrutinib in combination with rituximab-CHOP

These studies aim to improve progression-free survival and optimize treatment regimens for better patient outcomes.